Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD

NCT00574093 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age Related Macular Degeneration

Interventions

DRUG: Ranibizumab; Verteporfin

Sponsor

Fondazione G.B. Bietti, IRCCS